[Report Description]USA compounding pharmaceutical Market is valued approximately at USD 4.51 Billion in 2019 and is anticipated to grow with a healthy growth rate of more than 5.60% over the forecast period 2020-2027. Compounding is the preparation of a personalized drug mixture to meet a patient's specific need that cannot be fulfilled by drugs that are commercially available. The compounding pharmaceuticals is gaining a significant demand from various therapeutic areas such pain medication, dermatological applications, hormone replacement therapies and others. Therefore, rising number of skin conditions is stimulating the growth of market over the forecast years. According to the American Academy of Dermatology Association, the primary skin conditions rampant among individuals in the United States include acne, psoriasis and atopic dermatitis. The compounding pharmaceuticals are precisely recommended by the doctors & dermatologists for the common skin conditions such as acne and psoriasis. Acne is the most common skin condition which affects around 50 million American population every year. Around 85% of the individuals belonging to the age group of 12 to 24 years suffers at least one minor acne. In the present scenario, acne is on the escalating mode in the United States subsequently affecting up to 15% of female population in the country. In addition, Atopic dermatitis is considered as one of the leading skin conditions prevalent among the American population. According to American Academy of Dermatology Association, 1 in 10 individuals in United States would develop atopic dermatitis during their lifetime. The prevalence of atopic dermatitis impacts around 25% of the adolescent and 2-3% of adults in United States every year. Additionally, surging rate of geriatric population is driving the growth of market over the forecast years. However, Denied approval from Food & Drug administration for compounding pharmaceuticals is restraining the growth of market.